"Targeting the Breast Cancer-Associated HER2 Proto-Oncogene with Intracellularly-Generated Triple Helix-Forming Oligonucleotides."

According to an abstract presented by the authors to Southern or Western Regional meetings of the American Federation for Clinical Research, held February 2-4, 1995, and February 8-11, 1995, in New Orleans, Louisiana and Carmel, California, "The HER2/c-erbB2/neu proto-oncogene encodes a transmembrane growth factor receptor which is overexpressed in 11-41% of human breast carcinomas and is associated with increased tumor aggressiveness, increased resistance to chemotherapy, and decreased time of overall and disease-free patient survival. We have developed a method for downregulation of HER2 in overexpressing cell lines through the generation of intracellular triple helix-forming anti-HER2...

Want to see the full article?

• Purchase this article for only $3.00